CytomX Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $71.6M | $15.0M | $7.7M | $5.1M | $888.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $92.3M | $54.8M | $28.4M | $28.3M | $10.9M |
| SG&A Expense | $25.6M | $19.9M | $12.6M | $6.5M | $5.0M |
| Operating Income | $-46.3M | $-59.6M | $-33.2M | $-29.8M | $-15.0M |
| Operating Margin | -64.6% | -396.1% | -430.5% | -586.3% | -1,684.2% |
| Interest Expense | — | $1.7M | $1.7M | $487.0K | $254.0K |
| Pretax Income | $-43.6M | $-58.9M | $-35.4M | $-30.3M | $-15.1M |
| Income Tax Expense | $-513.0K | $-19.0K | $10.0K | $10.0K | $10.0K |
| Net Income | $-43.1M | $-58.9M | $-35.4M | $-30.3M | $-15.1M |
| Net Margin | -60.2% | -391.5% | -458.7% | -597.0% | -1,705.3% |
| EPS (Basic) | $-1.16 | $-1.63 | $-4.90 | $-35.25 | $-24.46 |
| EPS (Diluted) | $-1.16 | $-1.63 | $-4.90 | $-35.25 | $-24.46 |
| Shares Outstanding (Basic) | 38.5M | 36.5M | 36.0M | 996.5K | — |
| Shares Outstanding (Diluted) | 38.5M | 36.5M | 36.0M | 996.5K | — |
| Dividends Per Share | — | — | — | — | — |